Device Oncology

Trinav Infusion System

Payments companies reported to CMS as associated with Trinav Infusion System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$3.0Massociated payments (2023-2025)
1,761clinicians with associated payments
1company reporting

By year

2023 $1.2M
2024 $443K
2025 $1.4M

Payments reported as associated with Trinav Infusion System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Vascular & Interventional Radiology $1.8M
Diagnostic Radiology $687K
Surgical Oncology $214K
Nephrology (Internal Medicine) $126K
Internal Medicine $71K
Urology $48K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Trinav Infusion System

These are the largest totals companies reported as associated with Trinav Infusion System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Riad Salem Chicago, IL Vascular & Interventional Radiology $265,484.07
Robert Lewandowski Chicago, IL Vascular & Interventional Radiology $261,196.15
Alexander Kim Oxon Hill, MD Vascular & Interventional Radiology $253,641.17
Richard Marshall Jr New Orleans, LA Vascular & Interventional Radiology $198,140.30
Dennis Griffin Englewood, CO Diagnostic Radiology $162,359.69
David Porter Greenwood Village, CO Diagnostic Radiology $133,652.46
James Luethke Englewood, CO Diagnostic Radiology $126,920.00
Rekha Abichandani Cambridge, MA Nephrology (Internal Medicine) $126,316.68
Jonathan Lewis Westport, CT Surgical Oncology $114,750.00
John Hardaway Shenandoah, TX Surgical Oncology $96,247.84

Prescribed Trinav Infusion System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.